Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy
Open accessPublished version of a preprint
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Immune checkpoint inhibitors (ICI) are now routinely used in multiple cancers but may induce autoimmune-like side effects known as immune-related adverse events (irAE). Although classical autoimmune diseases have well-known risk factors, including age, gender, and seasonality, the clinical factors that lead to irAEs are not well-defined. To explore these questions, we assessed 455 patients with advanced melanoma treated with ICI at our center and a large pharmacovigilance database (VigiBase). We found that younger age was associated with a similar rate of any irAEs but more frequent severe irAEs and more hospitalizations (OR, 0.97 per year). Paradoxically, however, older patients had more deaths and increased length of stay (LOS) when hospitalized. This was partially due to a distinct toxicity profile: Colitis and hepatitis were more common in younger patients, whereas myocarditis and pneumonitis had an older age distribution both in our center and in VigiBase. This pattern was particularly apparent with combination checkpoint blockade with ipilimumab and nivolumab. We did not find a link between gender or seasonality on development of irAEs in univariate or multivariate analyses, although winter hospitalizations were associated with marginally increased LOS. This study identifies age-specific associations of irAEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“those irAEs with autoimmune correlates do not always share histopathologic findings in the involved tissue, other clinical findings, or demographic factor associations with the respective autoimmune phenomena”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Shah et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674 · cited 1×
“Colitis and hepatitis, which are associated with frequent hospitalizations but low death rates (10), were more common in the youngest age subset (16% and 11%, respectively) and decreased in prevalence with increasing age (Fig.”
BackgroundSelf-citationFulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Self-citationMyocarditis in Patients Treated With Immune Checkpoint Inhibitors
Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608
Self-citationPneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215 · cited 1×
“Indeed, one retrospective study has implicated diabetes and perhaps preexisting heart disease as a risk factor for myocarditis, although the relationship between smoking and pneumonitis is less clear (21, 22).”
BackgroundGender differences in autoimmune disease
Ngo, S. T., Steyn, F. J., & McCombe, P. A. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.04.004 · Cited by 1,074
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987
The epidemiology of autoimmune diseases
Cooper, G. S., & Stroehla, B. C. (2003) · Autoimmunity Reviews · doi:10.1016/s1568-9972(03)00006-5 · Cited by 880
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817
Self-citationIwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642
Self-citation
Cited by
Schneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,372
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Endocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441
Self-citationImmune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237
“Finally, ICI-based therapies have become first-line therapeutics in both adjuvant (given after the primary treatment to lower recurrence risk) and neoadjuvant (initial treatment as first step prior to the main treatment, usually surgery) settings, in addition to previous indications for advanced, disseminated, and tre…”
BackgroundSelf-citationNebhan, C. A., Cortellini, A., Ma, W., Ganta, T., Song, H., Ye, F., Irlmeier, R., Debnath, N., Saeed, A., Radford, M., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4960 · Cited by 160
Self-citation
Metadata
- Authors
- Shah, K. P., Song, H., Ye, F., Moslehi, J. J., Balko, J. M., Salem, J.-E., & Johnson, D. B.
- Affiliations
- Vanderbilt University (US)
- Vanderbilt University Medical Center (US)
- Inserm (FR)
- Venue
- Cancer Immunology Research
- Published
- 2020-07-01
- Volume
- 8
- Issue
- 7
- Pages
- 851-855
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- PMC
- PMC7334081
- OpenAlex
- W3021418236
- Cited by
- 64
- References
- 22
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 14 · 2023: 6 · 2022: 11 · 2021: 15 · 2020: 4
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- NIH (K23 CA204726, R01CA227481)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune-related adverse events, immune checkpoint inhibitors, PD-1 inhibitors, advanced melanoma, age as risk factor, colitis, hepatitis, myocarditis, pneumonitis, ipilimumab, nivolumab, hospitalization, length of hospital stay, pharmacovigilance, VigiBase
- MeSH terms
- Antineoplastic Agents, Immunological, Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Female, Hospitalization, Humans, Immunologic Factors, Immunotherapy, Length of Stay, Male, Melanoma, Middle Aged, Risk Factors, Young Adult, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy. https://app.cochat.ai/papers/10.1158/2326-6066.cir-19-0986
- The paper
- Shah, K. P., Song, H., Ye, F., Moslehi, J. J., Balko, J. M., Salem, J.-E., & Johnson, D. B. (2020). Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-19-0986
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.